

# Masamichi Sugimoto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/350083/publications.pdf>

Version: 2024-02-01

5  
papers

134  
citations

1937685

4  
h-index

2272923

4  
g-index

5  
all docs

5  
docs citations

5  
times ranked

254  
citing authors

| # | ARTICLE  | IF  | CITATIONS |
|---|--|-----|-----------|
| 1 | PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 335-344. | 3.3 | 0         |
| 2 | Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes. <i>Journal of Immunology</i> , 2021, 206, 1204-1214.  | 0.8 | 12        |
| 3 | Bevacizumab suppresses the growth of established non-small-cell lung cancer brain metastases in a hematogenous brain metastasis model. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 199-207.              | 3.3 | 24        |
| 4 | Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. <i>Anticancer Research</i> , 2019, 39, 1749-1760.   | 1.1 | 30        |
| 5 | Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model. <i>International Journal of Oncology</i> , 2017, 51, 425-434.   | 3.3 | 68        |